Recor
Menu
  • Patients
    • About Hypertension
    • Therapy
  • Healthcare Professionals
    • Our Technology
    • Clinical Evidence
      • RADIANCE II
      • RADIANCE-HTN CLINICAL TRIAL
      • RADIANCE-HTN SOLO RESULTS
      • RADIANCE-HTN TRIO RESULTS
    • Medical Education
  • Clinical Trials
  • About / Contact
    • Management
    • Contact
    • Patents
    • Careers
    • Code of Business Ethics
    • Product Feedback
    • Idea Portal
  • News & Press
Am I a Candidate?
  • Follow us on:
  • Facebook
  • Twitter
  • Instagram

News & Events

ReCor Medical To Release Clinical Trial Results May 23 at EuroPCR in Paris

May 17, 2018 by tracyrodriguez

PALO ALTO, Calif., May 17, 2018 / — ReCor Medical announced today that it will present the primary outcomes data from the SOLO study of its RADIANCE Global Clinical Trial Program of the Paradise™  Ultrasound Renal Denervation System for patients with hypertension during the Late Breaker Sessions at the EuroPCR 2018 Meeting in Paris on 23 May.

The RADIANCE Global Clinical Trial Program includes RADIANCE-HTN, ReCor’s randomized study of the Paradise Renal Denervation System in hypertensive patients in the US and Europe and the REQUIRE study of the Paradise System in resistant hypertensive patients in Japan and Korea.  RADIANCE-HTN involves two study Cohorts: “SOLO” –  whose subjects studied in the absence of anti-hypertensive medications, and “TRIO” – whose subjects are studied on a standardized anti-hypertensive medication.  Both Cohorts are randomized, blinded, sham-controlled, and independently powered for efficacy.  Randomization of the RADIANCE-HTN SOLO cohort study was completed in December, 2017, while the TRIO cohort is currently enrolling in 35 centers in the US and Europe.

The SOLO Cohort primary results will be presented during the Late Breaker Sessions at EuroPCR on May 23rd in Paris, France, by Co-Principal Investigator Laura Mauri, MD, MSc, Brigham & Women’s Hospital, Boston, MA.  In addition, ReCor Medical is sponsoring an RDN Symposium on the same day, with additional analysis, technical review and initial assessment of clinical impact of the SOLO results provided by Michel Azizi, MD, George Pompidou Medical Center (co-PI); Felix Mahfoud, MD, University Hospital Saarland; Roland Schmieder, MD, University Hospital Erlangen; Ajay Kirtane, MD, Columbia University Medical Center and Dr. Mauri.

“We are very pleased to be able to present the SOLO primary outcome data at the EuroPCR meeting, and to have such a distinguished panel of hypertension specialists and cardiologists review the potential impact of the Paradise System in the treatment of hypertension,” commented Andrew M. Weiss, ReCor, President & CEO. “During the past two years more than 500,000 patients sought information about the RADIANCE-HTN study – a strong indication of patient interest in device-based hypertension treatment.  With the completion of the primary outcome phase of our SOLO study, and continued progress in the TRIO cohort of RADIANCE-HTN, we are optimistic about the continued progress of study of the Paradise System, to support the potential for future clinical use.”

 

About ReCor Medical, Inc.

ReCor Medical is a private, development-stage, medical device company with the Paradise™ System, a proprietary, ultrasound-based system for intravascular denervation of the renal nerves (RDN).  RDN is a potential therapeutic option for treatment of hypertension, one of the most prevalent medical conditions.  The Paradise System bears a CE mark but is not approved for sale in the United States.  ReCor is conducting the RADIANCE-HTN clinical trial under an IDE from the US FDA in the United States and Europe.

Filed Under: News

Primary Sidebar

sidebar-alt

  • Patients
    • About Hypertension
    • Therapy
  • Healthcare Professionals
    • Our Technology
    • Clinical Evidence
      • RADIANCE II
      • RADIANCE-HTN CLINICAL TRIAL
      • RADIANCE-HTN SOLO RESULTS
      • RADIANCE-HTN TRIO RESULTS
    • Medical Education
  • Clinical Trials
  • About / Contact
    • Management
    • Contact
    • Patents
    • Careers
    • Code of Business Ethics
    • Product Feedback
    • Idea Portal
  • News & Press

Footer

The PARADISE™ system is approved for sale in markets regulated by the CE mark.
Investigational Device in the US, Limited by US Federal Law to Investigational Use Only in the United States
© ReCor Medical, Inc. All rights reserved 2021. PARADISE, RADIANCE, and the Paradise Swirl logo are trademarks of ReCor Medical, Inc.
The PARADISE System is covered by US Patent Nos. 6763722, 8715209, 9352171, 9358401, 9700372, 9707034, 9943666, 9981108, 10039901, 10230041, 10350440, 10368944, 10456605; Corresponding Patents OUS; Other Patents Pending US and OUS.

recormedical.com is ReCor Medical, Inc.’s United States web site (the Site). We control and operate this Site from the United States of America. This Site is intended for use by United States residents only and contains information regarding the Paradise System, which is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. If you are a non-U.S. resident, you may access this Site solely at your own risk and are responsible for compliance with local laws and regulations, if applicable. The trademarks, service marks and logos displayed on www.recormedical.com are registered and unregistered trademarks of ReCor Medical, Inc. PARADISE, RECOR MEDICAL, and the swirl design are ReCor Medical’s trade marks registered in the United States, the European Union, and Japan.

Sitemap | Contact | Privacy Policy | Terms & Conditions

  • Follow us on:
  • Facebook
  • Twitter
  • Instagram